الفهرس 
Thalassemia IntermediaOnly 14 pages are availabe for public view
 |  | from | 111 |  |  |
| | | from | 111 | | |
Abstract
Background: Thalassemias are genetic disorders in globin chain production. In individuals with Beta -thalassemia, there is either a complete absence of β-globin gene production (β0 -thalassemia) or a partial reduction (β+-thalassemia). Aim of the Work: Assessment of the effect of hydroxyurea treatment in patients with thalassemia intermedia on sperm parameters. This is accomplished by assessment of sperm parmeters at base line and reassessment after six month of treatment. Patients and Methods: This was a prospective follow-up study that included 10 fully pubertal patients with thalassemia intermedia who presented to the Haematology/Oncology Clinic at the Pediatrics Hospital, Ain Shams University. Verbal consents were obtained from the patients before enrollment in the study. The study protocol was approved by our localethical committee. Resuts: This study revealed that there were statistically a high difference between patients receiving hydroxyurea and those not receiving hydroxyurea in the first lab regarding Total sperm count (p<0.001). There were statistically a high significant difference between base line semen analysis and follow up semen analysis in patients receiving hydroxyurea regarding Total sperm count (p < 0.001).There was statistically a high significant difference between total sperm count total sperm count in million patients on hydroxyurea treatment 6.33 ± 3.54 (1-10.2) and patients six month off hydroxyurea treatment 45.99 ± 28.03(8.5-88) in patients receiving hydroxyurea (t= -5.252, p < 0.001).There were statistically high significant relations of total sperm count in patients on hydroxyurea treatment with hydroxyurea dose, hydroxyurea complinance and duration in patients receiving hydroxyurea (p < 0.05). There were statistically significant relations of total sperm count in patients six month off hydroxyurea treatment with hydroxyurea dose, hydroxyurea compliance and duration in patients receiving hydroxyurea (p < 0.05). Conclusion: HU is a safe medication in thalassemic patients, saving in blood transfusion costs and disease complications is remarkable.